Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease

Nuclear factor erythroid 2-related factor 2 (NRF2), a transcription factor which plays a critical role in maintenance of cellular redox, has been identified as a therapeutic target in a number of human diseases. Several reports have demonstrated beneficial effects of NRF2 manipulation in animal mode...

Full description

Saved in:
Bibliographic Details
Published in:Antioxidants 2021-01, Vol.10 (1), p.28
Main Authors: Neilson, Lee E, Quinn, Joseph F, Gray, Nora E
Format: Article
Language:English
Subjects:
Aging
Animal models
antioxidant
Antioxidants
biomarker
Biomarkers
Chronic obstructive pulmonary disease
Clinical trials
Gene expression
Human subjects
Inflammation
Kidney diseases
Leukocytes (mononuclear)
Literature reviews
Metabolism
Multiple sclerosis
Nuclear factor erythroid 2-related factor 2 (NRF2)
Oxidation
Oxidative stress
Peripheral blood mononuclear cell (PBMC)
Peripheral blood mononuclear cells
Peritoneal dialysis
Protein expression
Proteins
Smoking
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nuclear factor erythroid 2-related factor 2 (NRF2), a transcription factor which plays a critical role in maintenance of cellular redox, has been identified as a therapeutic target in a number of human diseases. Several reports have demonstrated beneficial effects of NRF2 manipulation in animal models of disease, and one NRF2-activating drug, dimethyl fumarate, is already approved for the treatment of multiple sclerosis. However, drug discovery is slowed due to a dearth of biomarkers which can inform target engagement and magnitude and duration of action. Peripheral blood mononuclear cells (PBMCs) are an accessible, minimally-invasive source of biomarkers which can be readily assayed and objectively monitored as a surrogate endpoint of NRF2 activation in clinical trials. We undertook a review of the literature on PBMC NRF2 measurements in human studies to explore its role as a suitable biomarker in various contexts of health and disease. It is clear that NRF2 and its target genes can be readily assayed from PBMCs in multiple disease contexts and may track with disease progression. Further work needs to be undertaken to evaluate its stability but should be considered as an exploratory marker in clinical trials targeting NRF2 activation.
ISSN:2076-3921
2076-3921
DOI:10.3390/antiox10010028